We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Clinical Data on New Assay Panel Demonstrates Accurate Assessment of Pancreatic Cancer Risk

By LabMedica International staff writers
Posted on 31 Jul 2025

Pancreatic cancer is the third-deadliest cancer in the US. More...

Early detection is key to improving the survival rate. One window to early diagnosis is pancreatic cystic lesions (PCL), a known precursor lesion for pancreatic cancer. Patients diagnosed with pancreatic cysts are at higher risk of pancreatic cancer, but many of these cystic lesions are benign, so risk stratification tools are critical. Now, new clinical validation data presented at ADLM 2025 highlights recent findings related to the stratification of PCLs, a complex and increasingly common clinical challenge.

The work builds on PanCystPro, a CLIA-cleared assay from Amplified Sciences (West Lafayette, IN, USA), which is designed to assist clinicians in the risk stratification of patients diagnosed with PCL by distinguishing between mucinous and non-mucinous cysts using comparatively less fluid. The PanCystPro test uses a proprietary platform that enables ultrasensitive detection of multiple biomarkers in small volumes of pancreatic cyst fluid. This multianalyte assay utilizes a robust algorithm and features a novel protease activity assay, enabling better biological insight to inform risk stratification of PCL. This multianalyte assay utilizes a robust algorithm and features a novel protease activity assay, enabling better biological insight to inform risk stratification of PCL.

This highly accurate test allows clinicians to define low-risk and/or benign pancreatic cysts, ruling out potential for malignancy, thus resulting in significant cost savings and patient peace of mind. In testing among several clinical cohorts, the assay provides the advantages of increased accuracy, high negative predictive value, a robust panel of biomarkers including the measurement of important protease activity, and a significantly reduced volume of pancreatic cyst fluid required. This test will address the need of gastroenterologists, pancreatic biliary surgeons, and other clinicians for better diagnostic tests to manage patients diagnosed with pancreatic cysts. At ADLM 2025, Mini Thomas, PhD, Principal Scientist, is highlighting recent findings related to the stratification of PCLs.

“The data show high accuracy and predictive value in grading dysplasia in pancreatic cystic lesions—a key risk factor for pancreatic cancer. These results highlight the potential of our diagnostic platform BioMatra and support the assay panel’s ability to reliably classify dysplasia in high-risk lesions, such as Intraductal Papillary Mucinous Neoplasms (IPMNs),” said Diana Caldwell, CEO of Amplified Sciences. “With minimal sample volume requirements, this approach will support earlier risk stratification, an important step given that nearly 80% of pancreatic cancer cases are diagnosed at a late stage.”

Related Links:
Amplified Sciences


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.